Maternal analgosedation and breastfeeding: guidance for the pediatrician
Vol. 4 No. 1 (2015), Articles
Vol. 4 No. 1 (2015)

Maternal analgosedation and breastfeeding: guidance for the pediatrician

Articles
https://doi.org/10.7363/040117
Published 2015-03-26
Karel Allegaert
Neonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium; Department of Development and Regeneration, KU Leuven, Leuven, Belgium
Johannes N. van den Anker
Division of Pediatric Clinical Pharmacology, Children’s National Medical Center, Washington, DC, USA; Departments of Pediatrics, Integrative Systems Biology, Pharmacology and Physiology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA; Intensive Care and Department of Pediatric Surgery, Erasmus MC-Sophia Children’s Hospital, Rotterdam, the Netherlands; Department of Paediatric Pharmacology, University Children’s Hospital Basel, Basel, Switzerland
JPNIM Vol. 4 N. 1 - Cover
PDF

Keywords

breastfeeding
analgosedation
safety
opioids
neonatal abstinence syndrome

How to Cite

Allegaert, K., & van den Anker, J. N. (2015). Maternal analgosedation and breastfeeding: guidance for the pediatrician. Journal of Pediatric and Neonatal Individualized Medicine (JPNIM), 4(1), e040117. https://doi.org/10.7363/040117
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

As part of analgosedative treatment modalities after delivery (e.g. caesarean related pain, birth related trauma, pre-existing pain syndromes), mothers are treated with different analgosedatives that may also affect the nursing infant. This review aims to summarize the available knowledge on commonly prescribed analgosedatives (opioids, intravenous and inhalational anesthetics, benzodiazepines, non-opioid analgesics, and local anesthetics) during breastfeeding.

We propose that the use of systemic non-opioid analgesics, local anesthetics, inhalational or intravenous anesthetics is safe when mothers are nursing. When systemic opioids are used, we recommend pediatricians to consider clinical monitoring of the infant for sedation. The duration of maternal exposure (> 4 days) and the presence of maternal signs of somnolence are hereby of additional relevance. We encourage research groups to report on their specific observations and expertise in order to further validate the current practices and guidance.

https://doi.org/10.7363/040117
PDF